Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
Released August 23, 2016 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--By the end of the third quarter of 2016, the Pharmaceutical-Biotech industry is expected to complete construction on a total of 268 North American capital and MRO (maintenance, repair and operations) projects. A recent survey of reported projects in Industrial Info's Pharmaceutical-Biotech Online Database reveals that the projects represent a total investment value (TIV) of $5.92 billion.
Click on the image at right for a graph detailing North American Pharmaceutical-Biotech projects completed in 3Q16 by region.
Sources for the third-quarter activity include private industry, commercial developers and universities. The projects reported include grassroot facilities, major building additions to existing sites and in-plant capital. The projects are a varied group in both size and focus. The project average TIV is $22 million, a little lower than usual, but that is due to the large number of summer maintenance projects.
Gilead Sciences (NASDAQ:GILD) (Foster City, California) expects to complete its 250 million grassroot sterile intravenous therapeutics plant in La Verne, California. Work on the 400,000-square-foot manufacturing facility began in early 2015. Located on a 23-acre site formerly owned by Trammel Crow (Dallas, Texas), the facility will also house research laboratories and distribution-warehouse space, along with central utilities. Project team members include Ferguson Pape Baldwin Architects, Rudolph & Sletten Construction and Acco Engineered Systems.
Across the country, Nanotherapeutics Incorporated (Alachua, Florida) tapped a project team that includes Causseaux, Hewett & Walpole Incorporated (engineers); RS&H (construction management) and The Whiting Turner Contacting Company, to construct a 145,000-square-foot flex-space building adjacent to its current facility. The new building will be equipped for nano-based production and development of manufacturing processes for drugs to treat bioterrorism and radiological threats in support of $400 million Department of Defense contract awarded in March 2013.
In Manati, Puerto Rico, Romark Laboratories (Tampa, Florida) invested $110 million to build a grassroot 150,000-square-foot facility for the production and R&D of small molecule cancer and infectious disease therapeutics (including components of its current product Alinia, and the product against influenza NT-300). The project team includes AMA Architects and Engineers and Caribbean Industrial Construction SE.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
Click on the image at right for a graph detailing North American Pharmaceutical-Biotech projects completed in 3Q16 by region. Sources for the third-quarter activity include private industry, commercial developers and universities. The projects reported include grassroot facilities, major building additions to existing sites and in-plant capital. The projects are a varied group in both size and focus. The project average TIV is $22 million, a little lower than usual, but that is due to the large number of summer maintenance projects.
Gilead Sciences (NASDAQ:GILD) (Foster City, California) expects to complete its 250 million grassroot sterile intravenous therapeutics plant in La Verne, California. Work on the 400,000-square-foot manufacturing facility began in early 2015. Located on a 23-acre site formerly owned by Trammel Crow (Dallas, Texas), the facility will also house research laboratories and distribution-warehouse space, along with central utilities. Project team members include Ferguson Pape Baldwin Architects, Rudolph & Sletten Construction and Acco Engineered Systems.
Across the country, Nanotherapeutics Incorporated (Alachua, Florida) tapped a project team that includes Causseaux, Hewett & Walpole Incorporated (engineers); RS&H (construction management) and The Whiting Turner Contacting Company, to construct a 145,000-square-foot flex-space building adjacent to its current facility. The new building will be equipped for nano-based production and development of manufacturing processes for drugs to treat bioterrorism and radiological threats in support of $400 million Department of Defense contract awarded in March 2013.
In Manati, Puerto Rico, Romark Laboratories (Tampa, Florida) invested $110 million to build a grassroot 150,000-square-foot facility for the production and R&D of small molecule cancer and infectious disease therapeutics (including components of its current product Alinia, and the product against influenza NT-300). The project team includes AMA Architects and Engineers and Caribbean Industrial Construction SE.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
